- Anthera (NASDAQ:ANTH) has bought Sollpura, described by the company as "a soluble, stable and non-porcine enzyme product" meant to treat patients with exocrine pancreatic insufficiency (i.e. low digestive enzyme levels), from Eli Lilly.
- Anthera plans to "sublicense all rights, obligations, and intellectual property for the development and commercialization of Sollpura" to a fully-owned subsidiary to be called Alkira Therapeutics. Alkira, in turn, will obtain funding to "advance Sollpura into a phase 3 pivotal registration trial as agreed with the [FDA] in 2013."
- Alkira is expected to make milestone payments following product approval and "certain annual sales achievements," and also pay royalties after certain sales thresholds are hit.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs